EUnetHTA 21 has published their second Joint Clinical Assessment on the Evoke Spinal Cord Stimulation (SCS) System. This advanced device utilizes Evoked Compound Action Potentials (ECAPs) to guide programming of stimulation parameters and provide real-time, closed-loop stimulation. This unique feature allows the Evoke System to adjust the stimulation output level for every pulse, maintaining the ECAP near the target amplitude. This stands in contrast to other commercially available SCS devices which do not employ spinal cord feedback to adjust stimulation.
The Evoke SCS is indicated for the treatment of chronic, intractable pain in the trunk and/or limbs. Chronic pain, unlike acute pain, persists long after the initial injury or illness has healed. The Evoke System is primarily used to treat chronic neuropathic, mixed neuropathic/nociceptive, or ischemic pain, all of which are caused by nervous system damage or dysfunction.
This system is designed for patients with chronic, intractable pain who are not contraindicated for the system. It represents a new generation of SCS because of its ECAP-guided programming, an enhancement to other available SCS systems.
Promising study results suggest that the Evoke System is comparable or superior to other treatments reported in literature. Clinical data from prospective investigations of the Evoke System support its safety and performance. The anticipated benefits of the Evoke System outweigh the risks, providing a compelling case for its use in treating chronic, intractable pain.
🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?
Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.
#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs
🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?
The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.
Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.
#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess
🔍 Are you up-to-date with the latest advancements in HPV testing for head and neck cancer?
Our comprehensive article looks into the innovation of diagnostic methods for HPV status determination in head and neck squamous cell carcinoma (HNSCC). From traditional p16 immunohistochemistry to innovative liquid biopsies, discover the critical role these advancements play in prognosis, treatment planning, and improving patient outcomes.
Look into this essential topic and see how these insights could revolutionize clinical practices.
#SyenzaNews #oncology #HealthTech #HealthcareInnovation
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
